BAP31 Modulates Mitochondrial Homeostasis Through PINK1/Parkin Pathway in MPTP Parkinsonism Mouse Models

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Parkinson's disease (PD) involves dopaminergic neuron loss, α-synuclein aggregation, and mitochondrial dysfunction.
• BAP31, an endoplasmic reticulum protein, has an unclear role in PD pathogenesis.

Purpose of the Study:

• To investigate the impact of BAP31 deficiency on PD progression using a mouse model.
• To elucidate the molecular mechanisms underlying BAP31's role in dopaminergic neurodegeneration.

Main Methods:

• Generated dopamine neuron-specific BAP31 conditional knockout (cKO) mice (Slc6a3cre-BAP31^fl/fl).
• Utilized MPTP-lesioned Parkinsonian models to assess behavioral and neuropathological changes.
• Investigated the PINK1-Parkin mitophagy pathway and BAP31's regulation of PINK1 transcription.

Main Results:

• BAP31 cKO mice showed exacerbated motor deficits and neuropathological hallmarks of PD after MPTP treatment.
• BAP31 deficiency disrupted mitochondrial homeostasis by suppressing the PINK1-Parkin mitophagy pathway.
• BAP31 was found to regulate PINK1 transcription via the transcription factor Engrailed Homeobox 1.

Conclusions:

• BAP31 acts as a neuroprotective modulator, mitigating PD-associated motor dysfunction.
• Preserving mitochondrial stability through BAP31 is crucial for neuroprotection in PD.
• BAP31 represents a potential therapeutic target for Parkinson's disease and other neurodegenerative disorders.